1 |
NCT02584270 |
Recruiting |
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue |
- Tongue Neoplasms
- Tongue Cancer
- Oral Cancer
|
- Device: Palatal Augmentation Prosthesis (PAP)
- Other: Articulation Therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Word intelligibility
- Sentence intelligibility
- Articulation at the word level of phonemes (consonant sounds)
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02584270 |
HUM00093723.1 |
PGSRT |
January 2, 2018 |
January 2020 |
June 2020 |
October 22, 2015 |
March 15, 2018 |
|
- University of Michigan Department of Oral and Maxillofacial Surgery and Hospital Dentistry
Ann Arbor, Michigan, United States
|
2 |
NCT03505879 |
Not yet recruiting New |
Next Generation Sequencing Detection of Lyme Disease |
- Lyme Disease
- Pediatric Infectious Disorder
- Erythema Migrans
|
|
Observational |
|
- Stony Brook University
- Karius, Inc.
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Ability of Next Generation Sequencing to detect Borrelia burgdorferi DNA in blood
- NGS detection of Borrelia burgdorferi DNA in blood compared to serology
- Changes in NGS detection of Borrelia burgdorferi DNA in blood over time
|
30 |
All |
1 Year to 17 Years (Child) |
NCT03505879 |
1205731-1 |
|
May 15, 2018 |
November 1, 2019 |
November 1, 2019 |
April 23, 2018 |
April 23, 2018 |
|
|
3 |
NCT03499808 |
Recruiting New |
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis |
- Amorphous, Eosinophilic, and Acellular Deposit
- Constipation
- Diarrhea
- (and 10 more...)
|
- Biological: Isatuximab
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall confirmed hematologic response rate
- Incidence of adverse events
- Organ response
- (and 2 more...)
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT03499808 |
S1702 NCI-2017-01375 U10CA180888 |
|
March 8, 2018 |
October 30, 2021 |
July 31, 2025 |
April 17, 2018 |
April 17, 2018 |
|
- SWOG
Portland, Oregon, United States
|
4 |
NCT03462329 |
Not yet recruiting |
Patient's Pretreatment Expectations About Post-Lyme Symptoms |
|
- Drug: Antibiotics (preferentially oral doxycycline 100 mg bid)
|
Interventional |
Not Applicable |
- University Medical Centre Ljubljana
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Occurrence of objective clinical manifestations of Lyme borreliosis and post-Lyme symptoms at 14 days postenrollment in patients treated for erythema migrans
- Occurrence of objective clinical manifestations of Lyme borreliosis and post-Lyme symptoms at 2 months postenrollment in patients treated for erythema migrans
- Occurrence of objective clinical manifestations of Lyme borreliosis and post-Lyme symptoms at 6 months postenrollment in patients treated for erythema migrans
- (and 2 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03462329 |
Pretreatment expectations |
|
June 1, 2018 |
June 1, 2022 |
June 1, 2022 |
March 12, 2018 |
March 12, 2018 |
|
|
5 |
NCT03305302 |
Recruiting |
Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL |
|
- Procedure: Sample of cancerous epithelium from the tongue
|
Observational |
|
- Centre Hospitalier Universitaire Dijon
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Immortalised human taste bud cells, isolated from the fungiform tastebuds of patients with cancer of the mobile tongue.
|
25 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03305302 |
ZWETYENGA 2017 |
|
April 5, 2017 |
April 2018 |
December 2018 |
October 9, 2017 |
October 9, 2017 |
|
- Chu Dijon Bourgogne
Dijon, France
|
6 |
NCT03288298 |
Not yet recruiting |
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line |
- Tongue Neoplasms
- Carcinoma
|
- Drug: luteolin
- Drug: nano-luteolin
|
Interventional |
Early Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- gene expression of Caspase 3 to detect apoptosis
- cell viability
|
4 |
All |
Child, Adult, Senior |
NCT03288298 |
CEBD-CU-2017-09-23 |
|
November 1, 2017 |
September 1, 2018 |
April 1, 2019 |
September 20, 2017 |
September 20, 2017 |
|
|
7 |
NCT03239834 |
Recruiting |
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making |
- Palatal Neoplasms
- Lip Neoplasm
- Gingival Neoplasms
- (and 4 more...)
|
|
Observational |
|
- Vigilant Biosciences, Inc.
- Pearl Pathways
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Association of RAPID results with oral cavity / oropharyngeal biopsy.
- Association of RAPID results with the clinical decision process for avoiding an immediate biopsy.
|
1000 |
All |
23 Years and older (Adult, Senior) |
NCT03239834 |
VIG-001 |
|
March 31, 2017 |
September 2018 |
December 2018 |
August 4, 2017 |
March 23, 2018 |
|
- Joel Epstein
Beverly Hills, California, United States - Biosolutions Clinical Research Center
La Mesa, California, United States - Loma Linda School of Dentistry
Loma Linda, California, United States - (and 9 more...)
|
8 |
NCT03181035 |
Recruiting |
Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer |
|
- Radiation: (18)F-Fluoroazomycin arabinoside
- Drug: Pimonidazole
|
Interventional |
Phase 1 Phase 2 |
- Sunnybrook Health Sciences Centre
- Sunnybrook Research Institute
- University of Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Cellular hypoxia correlation
- Hypoxic reference standard
- Registration quality
- Textural feature comparison
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03181035 |
FAITH 253-2015 |
FAITH |
January 25, 2018 |
December 2018 |
March 2019 |
June 8, 2017 |
April 6, 2018 |
|
- Odette Cancer Centre, Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
9 |
NCT03008330 |
Recruiting |
High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer |
|
- Biological: High-activity natural killer
|
Interventional |
Phase 1 Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Shenzhen Hank Bioengineering Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relief degree of tumors
- Progress free survival(PFS)
- Overall survival(OS)
|
20 |
All |
30 Years to 60 Years (Adult) |
NCT03008330 |
HANK-tongue |
|
December 2016 |
December 2017 |
December 2019 |
January 2, 2017 |
January 4, 2017 |
|
- Fuda cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China
|
10 |
NCT02985255 |
Recruiting |
Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue |
- Tongue Neoplasms
- Squamous Cell Carcinoma
- Anterior Tongue Squamous Cell Carcinoma
|
- Drug: Docetaxel
- Drug: Cisplatin
- Drug: 5FU
- (and 2 more...)
|
Interventional |
Phase 2 |
- HealthCare Global Enterprise Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tongue Preservation Rate
- Overall Survival
- Progression Free Survival
- Sensitivity and Specificity of PET-CT
|
30 |
All |
1 Year to 99 Years (Child, Adult, Senior) |
NCT02985255 |
HCG/SX/001/2016 |
|
April 2016 |
June 2017 |
June 2017 |
December 7, 2016 |
December 7, 2016 |
|
- HealthCare Global Enterprises Ltd
Bangalore, Karnataka, India
|
11 |
NCT02849379 |
Recruiting |
Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer |
|
- Device: Cryosurgery
- Biological: NK immunotherapy
|
Interventional |
Phase 1 Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Shenzhen Hank Bioengineering Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relief degree of tumors
- Progress free survival(PFS)
- Overall survival(OS)
|
30 |
All |
30 Years to 70 Years (Adult, Senior) |
NCT02849379 |
NK-tongue |
|
July 2016 |
July 2017 |
July 2019 |
July 29, 2016 |
July 29, 2016 |
|
- Fuda cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China
|
12 |
NCT02748707 |
Recruiting |
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study |
- Oral Squamous Cell Carcinoma
- Carcinoma of Buccal Mucosa
- Tongue Cancers
- Head and Neck Cancers
|
- Drug: Arm1
- Drug: Arm 2
- Drug: Arm 3
- Other: Arm 4
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in expression of selected biomarkers in tissue samples, assessed by immunohistochemistry (IHC) and PCR
- Clinical and radiological Change in tumor size and appearance
|
64 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02748707 |
830 |
ERLO-XIB |
August 2015 |
August 2018 |
August 2020 |
April 22, 2016 |
November 9, 2016 |
|
- Tata Memorial Center (TMC)
Mumbai, Maharashtra, India
|
13 |
NCT02414789 |
Recruiting |
Lyme Borreliosis and Early Cutaneous Diagnostic |
|
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Compare the sensitivity (percentage of positive tests) of the SRM / MS-MS to techniques of PCR and culture Borrelia
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02414789 |
6084 |
DIABOLYC |
August 2015 |
August 2019 |
August 2019 |
April 13, 2015 |
September 8, 2017 |
|
- Centre Hospitalo-Universitaire Jean Minjoz
Besancon, France - Centre Hospitalier William Morey
Chalon-sur-Saône, France - Hôpital Pasteur
Colmar, France - (and 4 more...)
|
14 |
NCT02245100 |
Recruiting |
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer |
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- Salivary Gland Squamous Cell Carcinoma
- Stage IIIA Non-small Cell Lung Cancer
- (and 27 more...)
|
- Other: Cytology specimen
- Other: Laboratory biomarker analysis
|
Observational |
|
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Predictive value of circulating tumor DNA for disease-free survival (DFS)/progression-free survival (PFS)
- Correlation between plasma tumor DNA levels and salivary tumor DNA levels
- Association between absence and presence of circulating tumor DNA mutation with the tumor burden
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02245100 |
14D.172 2014-010 |
|
July 22, 2014 |
July 2019 |
January 2020 |
September 19, 2014 |
January 17, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
15 |
NCT02147249 |
Recruiting |
Cytokines and Chemokines in Erythema Migrans |
|
- Drug: antibiotic treatment
|
Interventional |
Not Applicable |
- University Medical Centre Ljubljana
- University of Ljubljana School of Medicine, Slovenia
- Medical University of Vienna
- Harvard University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- inflammatory proteins in erythema migrans patients
- gene polymorphisms in erythema migrans patients
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT02147249 |
EM-0613 |
|
July 2013 |
December 2017 |
|
May 26, 2014 |
May 5, 2017 |
|
- UMC Ljubljana, Department of Infectious Diseases
Ljubljana, Slovenia
|
16 |
NCT01847326 |
Recruiting |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer |
- Recurrent Salivary Gland Cancer
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Recurrent Squamous Cell Carcinoma of the Larynx
- (and 8 more...)
|
- Drug: carboplatin
- Drug: paclitaxel albumin-stabilized nanoparticle formulation
- Drug: fluorouracil
- (and 5 more...)
|
Interventional |
Phase 1 |
- University of Chicago
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose of paclitaxel albumin-stabilized nanoparticle formulation in combination with fluorouracil, hydroxyurea, and radiation therapy, determined according to incidence of DLT graded using the National Cancer Institute (NCI) CTCAE 4.0
- Recommended phase II dose of paclitaxel albumin-stabilized nanoparticle formulation in combination with radiation therapy, determined according to incidence of DLT graded using the NCI CTCAE 4.0
- PFS
- (and 2 more...)
|
61 |
All |
18 Years and older (Adult, Senior) |
NCT01847326 |
12-1554 NCI-2012-02179 |
|
March 2013 |
April 2018 |
December 2018 |
May 6, 2013 |
May 23, 2017 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
|
17 |
NCT01816841 |
Recruiting |
Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care |
- Lip and Oral Cavity Squamous Cell Carcinoma
- Oral Cavity Verrucous Carcinoma
- Stage 0 Lip and Oral Cavity Cancer
- Tongue Cancer
|
- Procedure: fluorescence imaging
- Procedure: biopsy
- Procedure: examination
- Procedure: Comparison of surgical margins by COE vs. DVFE
|
Interventional |
Not Applicable |
- Ohio State University Comprehensive Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity and specificity of DVFE compared to visual inspection by conventional oral examination alone
- Differences between lesional margins identified by COE and DVFE
|
283 |
All |
18 Years and older (Adult, Senior) |
NCT01816841 |
OSU-08095 NCI-2012-02017 |
|
November 11, 2008 |
December 31, 2018 |
December 31, 2018 |
March 22, 2013 |
April 6, 2018 |
|
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States
|
18 |
NCT01806675 |
Recruiting |
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- (and 42 more...)
|
- Drug: fludeoxyglucose F 18
- Drug: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide
- Diagnostic Test: positron emission tomography
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- Sanjiv Sam Gambhir
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change in maximum standard uptake values (SUVmax) on 18F FPPRGD2 and 18F FDG PET
- Progression-free survival
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01806675 |
VARIMG0002 NCI-2013-00535 |
|
March 2013 |
March 2018 |
March 2019 |
March 7, 2013 |
March 14, 2017 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
19 |
NCT01473784 |
Recruiting |
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck |
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- (and 48 more...)
|
- Procedure: transoral robotic surgery
- Procedure: quality of life assessment
|
Interventional |
Not Applicable |
- Enver Ozer
- Ohio State University Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the feasibility of the TORS in patients with oral and laryngopharyngeal benign and malignant lesions.
- Assess the impact of TORS on the intra-operative surgical outcomes such as operative time, blood loss and complications.
- Assess the quality of life of the patients with TORS.
|
360 |
All |
18 Years and older (Adult, Senior) |
NCT01473784 |
OSU-07061 NCI-2011-03122 |
|
December 3, 2007 |
December 31, 2018 |
December 31, 2020 |
November 17, 2011 |
April 5, 2017 |
|
- Ohio State University Medical Center
Columbus, Ohio, United States
|
20 |
NCT01163994 |
Recruiting |
Antibiotic Treatment of Multiple Erythema Migrans |
- Multiple Erythema Migrans
|
- Drug: ceftriaxone
- Drug: doxycycline
- Other: erythema migrans patients treated with doxycycline
|
Interventional |
Not Applicable |
- University Medical Centre Ljubljana
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.
- Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.
- Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.
|
500 |
All |
15 Years and older (Child, Adult, Senior) |
NCT01163994 |
MEM-0510 |
|
June 2010 |
October 2017 |
October 2017 |
July 16, 2010 |
May 5, 2017 |
|
- UMC Ljubljana, Department of Infectious Diseases
Ljubljana, Slovenia
|
21 |
NCT00132327 |
Recruiting |
Analysis of Lyme Disease Lesions |
- Erythema Migrans Lesions
- Erythema Migrans
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00132327 |
050219 05-I-0219 |
|
August 17, 2005 |
|
|
August 19, 2005 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|